Research Analysts Issue Forecasts for VKTX FY2025 Earnings

Key Points

• Cantor Fitzgerald has lowered its FY2025 earnings estimate for Viking Therapeutics from ($2.57) to ($2.72), while also projecting FY2026 earnings at ($4.35) EPS.
• The company reported a quarterly EPS of ($0.58), missing the consensus estimate of ($0.44) by ($0.14).
• Viking Therapeutics has received a mix of ratings, with one sell rating, two hold ratings, ten buy ratings, and two strong buy ratings, indicating a consensus rating of "Moderate Buy".

Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for Viking Therapeutics in a report issued on Thursday, July 24th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the biotechnology company will post earnings per share of ($2.72) for the year, down from their previous forecast of ($2.57). Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Viking Therapeutics' current full-year earnings is ($1.56) per share. Cantor Fitzgerald also issued estimates for Viking Therapeutics' FY2026 earnings at ($4.35) EPS.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The biotechnology company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.14). During the same quarter last year, the business posted ($0.20) earnings per share. The company's revenue for the quarter was up NaN% compared to the same quarter last year.

A number of other research firms also recently weighed in on VKTX. Truist Financial reaffirmed a "buy" rating and set a $75.00 price target (down from $95.00) on shares of Viking Therapeutics in a research note on Monday, April 28th. Citigroup raised their price target on Viking Therapeutics from $31.00 to $38.00 and gave the stock a "neutral" rating in a research note on Thursday, July 24th. Morgan Stanley cut their price target on Viking Therapeutics from $105.00 to $102.00 and set an "overweight" rating for the company in a research note on Thursday, April 24th. Raymond James Financial cut their price target on Viking Therapeutics from $125.00 to $122.00 and set a "strong-buy" rating for the company in a research note on Thursday, July 24th. Finally, The Goldman Sachs Group began coverage on Viking Therapeutics in a report on Tuesday, April 8th. They set a "neutral" rating and a $30.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Viking Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $86.92.

Viking Therapeutics Price Performance

Viking Therapeutics stock traded down $0.20 during mid-day trading on Monday, hitting $33.51. The company's stock had a trading volume of 666,426 shares, compared to its average volume of 4,085,027. The firm's 50 day moving average is $28.85 and its 200 day moving average is $28.61. The company has a market cap of $3.77 billion, a PE ratio of -21.88 and a beta of 0.62. Viking Therapeutics has a 52-week low of $18.92 and a 52-week high of $81.73.

Insider Buying and Selling

In related news, CFO Greg Zante sold 4,266 shares of the firm's stock in a transaction on Thursday, July 3rd. The stock was sold at an average price of $27.76, for a total transaction of $118,424.16. Following the sale, the chief financial officer owned 168,660 shares of the company's stock, valued at $4,682,001.60. This trade represents a 2.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Marianna Mancini sold 4,266 shares of the firm's stock in a transaction on Thursday, July 3rd. The shares were sold at an average price of $27.77, for a total value of $118,466.82. Following the sale, the chief operating officer directly owned 377,535 shares in the company, valued at approximately $10,484,146.95. This trade represents a 1.12% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 35,421 shares of company stock valued at $984,405 over the last 90 days. 4.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. FIL Ltd raised its position in shares of Viking Therapeutics by 116.8% in the 4th quarter. FIL Ltd now owns 1,203 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 648 shares in the last quarter. Quarry LP raised its position in shares of Viking Therapeutics by 1,621.4% in the 1st quarter. Quarry LP now owns 1,205 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 1,135 shares in the last quarter. CIBC Private Wealth Group LLC raised its position in shares of Viking Therapeutics by 170.2% in the 4th quarter. CIBC Private Wealth Group LLC now owns 1,351 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 851 shares in the last quarter. Parallel Advisors LLC raised its position in shares of Viking Therapeutics by 64.8% in the 1st quarter. Parallel Advisors LLC now owns 1,363 shares of the biotechnology company's stock worth $33,000 after acquiring an additional 536 shares in the last quarter. Finally, Kapitalo Investimentos Ltda bought a new position in shares of Viking Therapeutics in the 4th quarter worth about $63,000. 76.03% of the stock is owned by institutional investors.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.